Aflibercept: A review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 2355-2371

  Balaratnasingam, Chandrakumar ^a,b,c   Dhrami Gavazi, Elona ^a,b,d   McCann, Jesse T ^a,b,d,e   Ghadiali, Quraish ^a,b   Bailey Freund, K ^a,b,d,e  

^a Ear and Throat Hospital ^*  (United States)

^b EAR AND THROAT HOSPITAL   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Edward S Harkness Eye Institute   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aflibercept; Age related macular degeneration; Choroidal neovascularization; Clinical trial; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; COMPLEMENT FACTOR D; COMPLEMENT INHIBITOR; PEGAPTANIB; PLACEBO; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

AGE RELATED MACULAR DEGENERATION; BINDING AFFINITY; CLINICAL TRIAL (TOPIC); CONJUNCTIVAL HEMORRHAGE; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE PAIN; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MECHANICS; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPOIDAL CHOROIDAL VASCULOPATHY; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINAL THICKNESS; REVIEW; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UNITED STATES; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

EID: 84951193489     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S80040     Document Type: Review

References (131)

1. Friedman DS, O'Colmain BJ, Munoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122(4): 564-572.
2. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003; 121(4): 519-526.
3. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-e116.
4. Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol. 2010; 149(6): 939-946. e931.
5. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005; 112(4): 533-539.
6. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2007; (3): CD004763.
7. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999; 117(10): 1329-1345.
8. Eandi CM, Giansanti F, Virgili G. Macular translocation for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008; (4): CD006928.
9. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014; 8: CD005139.
10. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008; 92(12): 1606-1611.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1419-1431.
12. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1432-1444.
13. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20): 1897-1908.
14. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900): 1258-1267.
15. Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009; 18(10): 1573-1580.
16. Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther. 2013; 7: 711-722.
17. Bazan NG. Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2007; 48(11): 4866-4881; biography 4864-4865.
18. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009; 106(44): 18751-18756.
19. Bai Y, Ma JX, Guo J, et al. Muller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol. 2009; 219(4): 446-454.
20. Ablonczy Z, Dahrouj M, Marneros AG. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J. 2014; 28(5): 2369-2379.
21. Yang XM, Yafai Y, Wiedemann P, et al. Hypoxia-induced upregulation of pigment epithelium-derived factor by retinal glial (Muller) cells. J Neurosci Res. 2012; 90(1): 257-266.
22. Shirinifard A, Glazier JA, Swat M, et al. Adhesion failures determine the pattern of choroidal neovascularization in the eye: a computer simulation study. PLoS Comput Biol. 2012; 8(5): e1002440.
23. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis. 1999; 5: 34.
24. Funk M, Karl D, Georgopoulos M, et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009; 116(12): 2393-2399.
25. Muether PS, Neuhann I, Buhl C, Hermann MM, Kirchhof B, Fauser S. Intraocular growth factors and cytokines in patients with dry and neovascular age-related macular degeneration. Retina. 2013; 33(9): 1809-1814.
26. Girmens JF, Sahel JA, Marazova K. Dry age-related macular degeneration: a currently unmet clinical need. Intractable Rare Dis Res. 2012; 1(3): 103-114.
27. Singer M. Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29.
28. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008; 27(4): 372-390.
29. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006; 168(6): 2036-2053.
30. Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P. Transforming growth factor-beta 1 (TGF-β1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol. 2009; 219(2): 449-458.
31. Ogata N, Matsushima M, Takada Y, et al. Expression of basic fibroblast growth factor mRNA in developing choroidal neovascularization. Curr Eye Res. 1996; 15(10): 1008-1018.
32. Skeie JM, Zeng S, Faidley EA, Mullins RF. Angiogenin in age-related macular degeneration. Mol Vis. 2011; 17: 576-582.
33. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003; 44(7): 3186-3193.
34. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996; 122(3): 393-403.
35. Tatar O, Shinoda K, Adam A, et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration. Exp Eye Res. 2006; 83(2): 329-338.
36. Wang S, Sorenson CM, Sheibani N. Lack of thrombospondin 1 and exacerbation of choroidal neovascularization. Arch Ophthalmol. 2012; 130(5): 615-620.
37. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001; 188(2): 253-263.
38. Gunda V, Sudhakar YA. Regulation of tumor angiogenesis and choroidal neovascularization by endogenous angioinhibitors. J Cancer Sci Ther. 2013; 5(12): 417-426.
39. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003; 22(6): 721-748.
40. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17(11): 1359-1370.
41. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. 2001. Retina. 2012; 32(Suppl 1): 416-434.
42. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina. 2008; 28(3): 375-384.
43. Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol. 2014; 158(4): 769-779. e762.
44. Gass JD. Stereoscopic Atlas of Macular Diseases. 4th ed. St Louis, MO: Mosby; 1997.
45. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010; 30(9): 1333-1349.
46. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997; 12(1): 99-109.
47. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998; 105(3): 412-416.
48. Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 2009; 23(9): 1812-1818.
49. Skold MK, von Gertten C, Sandberg-Nordqvist AC, Mathiesen T, Holmin S. VEGF and VEGF receptor expression after experimental brain contusion in rat. J Neurotrauma. 2005; 22(3): 353-367.
50. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006; 103(7): 2328-2333.
51. Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D. Characterization of peroxidized lipids in Bruch's membrane. Retina. 1999; 19(2): 141-147.
52. McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009; 50(10): 4982-4991.
53. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005; 6(2): 209.
54. Iyer S, Acharya KR. Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS J. 2011; 278(22): 4304-4322.
55. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13(1): 9-22.
56. Wei MH, Popescu NC, Lerman MI, Merrill MJ, Zimonjic DB. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet. 1996; 97(6): 794-797.
57. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991; 266(18): 11947-11954.
58. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9(6): 669-676.
59. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol. 2002; 4(1): E2-E5.
60. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7(5): 359-371.
61. Djordjevic S, Driscoll PC. Targeting VEGF signalling via the neuropilin co-receptor. Drug Discov Today. 2013; 18(9-10): 447-455.
62. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci. 2006; 63(5): 601-615.
63. Ulyatt C, Walker J, Ponnambalam S. Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochem Biophys Res Commun. 2011; 404(3): 774-779.
64. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap-Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R D. 2008; 9(4): 261-269.
65. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003; 9(1): 47-52.
66. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2): 171-185.
67. Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002; 99(17): 11393-11398.
68. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep. 2011; 1: e5.
69. Christoforidis JB, Carlton MM, Knopp MV, Hinkle GH. PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci. 2011; 52(8): 5899-5903.
70. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007; 114(12): 2179-2182.
71. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114(5): 855-859.
72. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010; 51(11): 5403-5420.
73. Smelser GK, Ishikawa T, Pei YF. Electron Microscopic Studies of Intra-retinal Spaces: Diffusion of Particulate Materials. Vol II. Stuggart, Germany: Schattauer-Verlag; 1965.
74. Tornquist P, Alm A, Bill A. Permeability of ocular vessels and transport across the blood-retinal-barrier. Eye (Lond). 1990; 4(Pt 2): 303-309.
75. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007; 27(9): 1260-1266.
76. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014; 98(12): 1636-1641.
77. EYLEA™ (aflibercept) injection [US prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2012.
78. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119(12): 2537-2548.
79. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003; 195(2): 241-248.
80. Nork TM, Dubielzig RR, Christian BJ, et al. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol. 2011; 129(8): 1042-1052.
81. Nguyen QD, Shah SM, Hafiz G, et al; CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006; 113(9): 1522. e1-1522. e14.
82. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(11): 2141-2148. e2141.
83. Heier JS, Boyer D, Nguyen QD, et al; CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011; 118(6): 1098-1106.
84. Brown DM, Heier JS, Ciulla T, et al; CLEAR-IT 2 Investigators. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011; 118(6): 1089-1097.
85. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014; 121(1): 193-201.
86. Comparison of Age-related Macular Degeneration Treatments Trials Research Group; Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7): 1388-1398.
87. Park UC, Shin JY, McCarthy LC, et al. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients. Mol Vis. 2014; 20: 1680-1694.
88. Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013; 97(11): 1443-1446.
89. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol. 2007; 91(10): 1318-1322.
90. Suzuki M, Nagai N, Izumi-Nagai K, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014; 98(9): 1186-1191.
91. Otsuji T, Nagai Y, Sho K, et al. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol. 2013; 7: 1487-1490.
92. Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015; 29(10): 1397-1398.
93. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009; 29(6): 723-731.
94. Ehlken C, Jungmann S, Bohringer D, Agostini HT, Junker B, Pielen A. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond). 2014; 28(5): 538-545.
95. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013; 156(1): 29-35. e22.
96. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013; 156(1): 15-22. e11.
97. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013; 156(1): 23-28. e22.
98. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013; 33(8): 1605-1612.
99. Cho H, Weber ML, Shah CP, Heier JS. Initial utilization of aflibercept in exudative age-related macular degeneration. Eur J Ophthalmol. 2014; 24(4): 576-581.
100. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014; 121(1): 188-192.
101. Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. 2014; 2014: 273754.
102. Griffin DR, Richmond PP, Olson JC. Intravitreal aflibercept outcomes in patients with persistent macular exudate previously treated with bevacizumab and/or ranibizumab for neovascular age-related macular degeneration. J Ophthalmol. 2014; 2014: 497178.
103. Broadhead GK, Hong T, Zhu M, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina. 2015; 35(5): 975-981.
104. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond). 2013; 27(5): 663-667; quiz 668.
105. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014; 28(7): 895-899.
106. Schachat AP. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2013; 156(1): 1-2. e1.
107. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). 1990. Retina. 2012; 32(Suppl 1): 1-8.
108. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995; 15(2): 100-110.
109. Wen F, Chen C, Wu D, Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2004; 242(8): 625-629.
110. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004; 49(1): 25-37.
111. Dansingani K, Naysan J, Balaratnasingam C, Freund K. En Face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. Epub August 12, 2015.
112. Balaratnasingam C, Lee WK, Koizumi H, Dansingani KK, Inoue M, Freund KB. Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina. Epub September 23, 2015.
113. Gallego-Pinazo R, Dolz-Marco R, Gomez-Ulla F, Mrejen S, Freund KB. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014; 3(4): 111-115.
114. Hosokawa M, Shiraga F, Yamashita A, et al. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015; 99(8): 1087-1091.
115. Ijiri S, Sugiyama K. Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2015; 253(3): 351-357.
116. Yamamoto A, Okada AA, Kano M, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. Epub September 16, 2015.
117. Yamashita M, Nishi T, Hasegawa T, Ogata N. Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab. Clin Ophthalmol. 2014; 8: 343-346.
118. Miura M, Iwasaki T, Goto H. Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol. 2013; 7: 1591-1595.
119. Koizumi H, Kano M, Yamamoto A, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015; 159(4): 627-633.
120. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol. 2010; 94(8): 1045-1051.
121. Ogura Y, Terasaki H, Gomi F, et al; VIEW 2 Investigators. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015; 99(1): 92-97.
122. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012; 119(2): 321-326.
123. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013; 33(1): 179-187.
124. Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015; 122(9): 1802-1810.
125. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010; 128(10): 1273-1279.
126. Semeraro F, Morescalchi F, Duse S, Gambicorti E, Romano MR, Costagliola C. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opin Drug Saf. 2014; 13(6): 785-802.
127. Braekkan SK, Hald EM, Mathiesen EB, et al. Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arterioscler Thromb Vasc Biol. 2012; 32(2): 487-491.
128. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test I. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001; 119(7): 1050-1058.
129. Yuzawa M, Fujita K, Wittrup-Jensen KU, et al. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology. 2015; 122(3): 571-578.
130. Wijeyakumar W, Hong T, Broadhead T, Li H, Zhu M, Chang AA. Changes in quality of life among patients treated with aflibercept for neovascular age-related macular degeneration (nAMD). Poster presented at: ARVO 2014 Annual Meeting Abstracts, May 6, 2014, Orlando, FL.
131. VEGF Trap-Eye (aflibercept ophthalmic solution) Briefing Document. Available from: http: //www. fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM259143. pdf. Accessed November 17, 2015.